Is the business good?
How good a business is NVAX?
Novavax, Inc. keeps −13% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−13%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- −8.1%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 59%
R&D as % of revenue
- Gross margin
- 85%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −88% |
| FY2021 | −147% |
| FY2022 | −33% |
| FY2023 | −58% |
| FY2024 | −36% |
| FY2025 | 40% |
Details›
- Gross margin12 months to Q1 2026
- 85%
- Operating margin12 months to Q1 2026
- −13%
- Net margin12 months to Q1 2026
- −15%
- Free cash flow margin
- −16%
- R&D as % of revenue
- 59%
- Revenue, trailing twelve months
- $596M
- Free cash flow, trailing twelve months
- −$97M
- Net income, trailing twelve months
- −$88M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.